Literature DB >> 18596196

Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean?

Ya-Chen Tina Shih1, Michael T Halpern.   

Abstract

While the past decade has seen the development of multiple new interventions to diagnose and treat cancer, as well as to improve the quality of life for cancer patients, many of these interventions have substantial costs. This has resulted in increased scrutiny of the costs of care for cancer, as well as the costs relative to the benefits for cancer treatments. It is important for oncologists and other members of the cancer community to consider and understand how economic evaluations of cancer interventions are performed and to be able to use and critique these evaluations. This review discusses the components, main types, and analytic issues of health economic evaluations using studies of cancer interventions as examples. We also highlight limitations of these economic evaluations and discuss why members of the cancer community should care about economic analyses.

Entities:  

Mesh:

Year:  2008        PMID: 18596196     DOI: 10.3322/ca.2008.0008

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  25 in total

1.  The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer.

Authors:  T Younis; D Rayson; C Skedgel
Journal:  Curr Oncol       Date:  2011-12       Impact factor: 3.677

2.  Modeling the cost-effectiveness of strategies for treating esophageal adenocarcinoma and high-grade dysplasia.

Authors:  Louisa G Gordon; Nicholas G Hirst; George C Mayne; David I Watson; Timothy Bright; Wang Cai; Andrew P Barbour; Bernard M Smithers; David C Whiteman; Simon Eckermann
Journal:  J Gastrointest Surg       Date:  2012-05-30       Impact factor: 3.452

3.  Docetaxel-carboxymethylcellulose nanoparticles display enhanced anti-tumor activity in murine models of castration-resistant prostate cancer.

Authors:  Bryan Hoang; Mark J Ernsting; Mami Murakami; Elijus Undzys; Shyh-Dar Li
Journal:  Int J Pharm       Date:  2014-05-20       Impact factor: 5.875

4.  Cost and effectiveness of video-assisted thoracoscopic surgery for clinical stage I non-small cell lung cancer: a population-based analysis.

Authors:  Hsin-Yuan Fang; Fei-Yuan Hsiao; Hsu-Chih Huang; Yu-Sen Lin; Chih-Yi Chen; Shwn-Huey Shieh; Pin-Ru Chen; Chein-Kuang Chen; Chun-Ru Chien
Journal:  J Thorac Dis       Date:  2014-12       Impact factor: 2.895

5.  Attitude of Iranian Medical Oncologists Toward Economic Aspects, and Policy-making in Relation to New Cancer Drugs.

Authors:  Rajabali Daroudi; Mehrzad Mirzania; Kazem Zendehdel
Journal:  Int J Health Policy Manag       Date:  2015-10-20

Review 6.  Cost-Utility Analysis of Cancer Prevention, Treatment, and Control: A Systematic Review.

Authors:  Aaron N Winn; Donatus U Ekwueme; Gery P Guy; Peter J Neumann
Journal:  Am J Prev Med       Date:  2015-10-23       Impact factor: 5.043

7.  Cost-effectiveness of chemotherapy combined with thoracic radiotherapy versus chemotherapy alone for limited stage small cell lung cancer: A population-based propensity-score matched analysis.

Authors:  Chun-Ru Chien; Te-Chun Hsia; Chih-Yi Chen
Journal:  Thorac Cancer       Date:  2014-10-23       Impact factor: 3.500

Review 8.  Economic evaluation of therapeutic cancer vaccines and immunotherapy: a systematic review.

Authors:  Daniel M Geynisman; Chun-Ru Chien; Fabrice Smieliauskas; Chan Shen; Ya-Chen Tina Shih
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 9.  When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology.

Authors:  Dan Greenberg; Craig Earle; Chi-Hui Fang; Adi Eldar-Lissai; Peter J Neumann
Journal:  J Natl Cancer Inst       Date:  2010-01-07       Impact factor: 13.506

10.  Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy.

Authors:  J Rafael Sierra; Virna Cepero; Silvia Giordano
Journal:  Mol Cancer       Date:  2010-04-12       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.